Old friends, new ways: Revisiting extended lymphadenectomy and neoadjuvant chemotherapy to improve outcomes

Current Opinion in Urology

Volumn 14, Issue 5, 2004, Pages 251-257

  Busby, J Erik ^a   Evans, Christopher P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bladder cancer; Extended lymphadenectomy; Lymph node dissection; Neoadjuvant chemotherapy; Transitional cell carcinoma

Indexed keywords

ANTIINFECTIVE AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FOLINIC ACID; METHOTREXATE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; BLADDER CANCER; CANCER CELL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CYSTECTOMY; HUMAN; LYMPHADENECTOMY; METASTASIS; MORBIDITY; ORGAN PRESERVATION; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE;

CHEMOTHERAPY, ADJUVANT; HUMANS; LYMPH NODE EXCISION; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 4344574318     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200409000-00002     Document Type: Review

References (36)

1. Sherif A, Rintala E, Mestad O, et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer - Nordic cystectomy trial 2. Scand J Urol Nephrol 2002; 36:419-425.
2. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003; 361:1927-1934.
3. Wallace DMA, Raghavan D, Kelly KA, et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991; 67:608-615.
4. Martinez-Pineiro JA, González M, Arocena F, et al. Neoadjuvant cisplation chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomised phase III study. J Urol 1995; 153:964-973.
5. Abol-Enein H, El-Mekresh M, El-Baz M, Ghoneim MA. Neo-adjuvant chemotherapy in the treatment of invasive transitional bladder cancer. A controlled prospective randomised study. Br J Urol 1997; 79 (suppl 4):174.
6. Malmström P-U, Rintala E, Wahlqvist R, et al. Five year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial 1. J Urol 1996; 155:1903-1906.
7. Bassi P, Pappagallo GL, Sperandio P, et al. Neoadjuvant MVAC chemotherapy of invasive bladder cancer: results of a multicenter phase III trial. J Urol 1999; 161:264A.
8. International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 1999; 354:533-540.
9. Sengeløv L, von der Maase H, Lundbech F, et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle invasive bladder tumors. Acta Oncologia 2002; 41:447-456.
10. Sherif A, Rintala E, Mestad O, et al. Neoadjuvant cisplatin-methotrexate chemotherapy of invasive bladder cancer. Nordic Cystectomy Trial 2. Scand J Urol Nephrol 2002; 6:419-425.
11. Natale RB, Grossman HB, Blumenstein B, et al. SWOG 8710 (INT-0800). Randomized phase III trial of neoadjuvant MVAC+cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. Proc Am Soc Clin Oncol 2001; 20:3.
12. Coppin CML, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 1996; 14: 2901-2907.
13. Shearer RJ, Chilvers CED, Bloom HJG, et al. Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report. Br J Urol 1988; 62:558-564.
14. Leissner J, Ghoneim MA, Abol-Enein H, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol 2004; 171:139-144.
15. Herr HW, Bochner BH, Dalbagni G, et al. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 2002; 167:1295-1298.
16. Konety BR, Joslyn SA, O'Donnell MA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol 2003; 169:946-950.
17. Stein JP, Cai J, Groshen S, Skinner DG. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol 2003; 170:35-41.
18. Herr HW. Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. Urology 2003; 61:105-108.
19. Poulsen AL, Horn T, Steven K. Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol 1998; 160:2015-2019; discussion 2020.
20. Leissner J, Hohenfellner R, Thuroff JW, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int 2000; 85:817-823.
21. Skinner DG. Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference. J Urol 1982; 128:34-36.
22. Mills RD, Turner WH, Fleischmann A, et al. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J Urol 2001; 166:19-23.
23. Konety BR, Joslyn SA. Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol 2003; 170:1765-1771.
24. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19:666-675.
25. Vieweg J, Gschwend JE, Herr HW, Fair WR. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 1999; 161:449-454.
26. Brössner C, Pycha A, Toth A, et al. Does extended lymphadenectomy increase the morbidity of radical cystectomy? BJU Int 2004; 93:64-66.
27. Ghoneim MA, El-Mekresh MM, Mokhtar AA, et al. A predictive model of survival after radical cystectomy for carcinoma of the bladder. BJU Int 2000; 85:811-816.
28. Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 2004; 45:297-303.
29. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349:859-866.
30. Bassi P, Pagano F, Papagallo G, et al. Neo-Adjuvant M-VAC of invasive bladder cancer: the G.U.O.N.E. multicenter phase III trial. Eur Urol 1998; 33:142.
31. Winquist E, Kirchner TS, Segal R, et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004; 171:561-569.
32. Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998; 16:1298-1301.
33. Solsona E, Iborra I, Ricos JV, et al. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term followup of a prospective study. J Urol 1998; 159:95-98; discussion 98-99.
34. Solsona E, Iborra I, Ricos JV, et al. Feasibility of transurethral resection for muscle-infiltrating carcinoma of the bladder: prospective study. J Urol 1992; 147:1513-1515.
35. Sternberg CN, Pansadoro V, Calabro F, et al. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. Ann Oncol 1999; 10:1301-1305.
36. Thomas DJ, Roberts JT, Hall RR, Reading J. Radical transurethral resection and chemotherapy in the treatment of muscle-invasive bladder cancer: a long-term follow-up. BJU Int 1999; 83:432-437.